Little information exists concerning differing levels of regulation occurring during human megakaryocyte development. We hypothesize that megakaryocytic proliferation and maturation is controlled by two, synergistic regulatory factors. One, megakaryocyte colony-stimulating activity, is an obligate requirement for colony formation and drives the development of relatively immature cells. Megakaryocyte colony-stimulating activity is a functional component of the human recombinant proteins, interleukin 3 or GM-CSF. Human recombinant growth factors, interleukin 1, interleukin 6, or crythropoietin, do not effect megakaryocyte development either alone or in combination with interleukin 3. Full maturation requires a second synergistic activity which increases megakaryocyte number, size, and cytoplasmic and antigenic content. In culture, this synergistic regulator augments maturation by increasing the number of colonies, colony cellularity, and size. In suspension cultures, this cofactor increases megakaryocyte cytoplasmic and antigenic content, and shifts the morphological distribution from immature to mature megakaryocytes. Finally, this activity also increases the number of antigen positive megakaryocytes, either by stimulating proliferation or conversion of antigen-negative to antigen-positive cells. Comparative studies of megakaryocytic regulation suggests that this in vitro regulator mimicks some of the known effects of thrombopoietin in vivo.
Introduction
The existence of multiple regulators that act to coordinate hematopoietic differentiation is established for erythrocytic and granulocytic progenitor cells (1) (2) (3) (4) . In the megakaryocytic lineage, studies on the sera of patients with platelet/megakaryocyte dyscrasias suggest a similar pluralistic control of megakaryocyte development (5, 6) . In vitro studies show that megakaryocyte colony formation requires an activity that regulates progenitor cell proliferation (6, 7) . We hypothesized that the regulation of human megakaryocyte colony development may also require additional activities that augment megakaryocyte colony development presumably by affecting differentiation (8-1 1) .
Various sources of human megakaryocyte colony-stimulating activities (Mk-CSA)' exist (12) (13) (14) (15) (16) . Among these are
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1. Abbreviations used in this paper: BICM, human bladder carcinoma (5637)-conditioned media; BPA, burst-promoting activity; CM, conconditioned media from phytohemagglutinin-stimulated peripheral blood leukocytes (PHA-LCM) (12, 13) , or plasma/ sera obtained from patients with aplastic anemia (14) , amegakaryocytic thrombocytopenia (15) , or rebound phases of chemotherapy (16) . However, scarcity, problems with sample complexity, and patient/donor variability make these difficult sources for purification and/or in vitro characterization of megakaryocyte regulators.
We report that optimal in vitro human megakaryocyte colony development requires two regulatory activities. Mk-CSA, a functional activity of interleukin 3 (IL-3) or granulocyte/ macrophage colony-stimulating factor (GM-CSF), is obligate for colony formation and alone stimulates limited megakaryocyte development. A second auxiliary activity, which lacks the solitary ability to stimulate megakaryocyte colonies, acts synergistically with Mk-CSA to augment megakaryocyte colony development. Moreover, this activity regulates megakaryocytic size and the expression of megakaryocytic antigens.
Methods Preparation ofbone marrow cells
After we received informed consent, bone marrow aspirates were obtained from the posterior iliac crest of normal volunteers (n = 41, age 18-35 yr, 24 males, 17 females). Volunteers were reportedly free of pharmaceuticals for 3 wk before the aspiration.
Bone marrow cells were aspirated into syringes containing 100 U of preservative-free sodium heparin (University of Michigan) in normal saline. In order to prevent peripheral blood dilution, aspirate volumes were kept at 0.5-0.8 ml. Aspirates were immediately mixed with 100 yd of McCoy's 5A media (see below) containing 100-125 U DNase I (Sigma Chemical Co., St. Louis, MO). The addition of DNase to the samples improved the recovery of cells after density separation. The aspirate was diluted with McCoy's 5A media (Gibco, Grand Island, New York), layered over ficoll/diatrizoate (density = 1.077 g cm-3, Histopaque, Sigma Chemical Co.), and spun for 20 min at 400 g (mononuclear cell recovery = 7.9±4.6 X 107 cells, n = 17). The interface cells were collected, washed twice, and subjected to two rounds of plastic adherence. For adherence, low-density marrow cells were incubated (3 X 105/ml) in McCoy's 5A containing 5% FCS for 1 h at 37°C, after which the suspension cells were removed and subjected to a second adherence step. The resultant nonadherent, low-density cells (NALD; . 0.1% macrophages) were used as target cells in all experiments.
Hematopoietic progenitor cell assays
Progenitor cells were cultured in methylcellulose-based assays as described by Messner et al. (12) , and in a modification of a previously described agar system (10, 11 Gibco), 7.5% sodium bicarbonate, and 0.25% glucose. These cells were grown to confluence, and media were conditioned for 5 d. Supernatant media were decanted, centrifuged, filter sterilized, and stored at -800C.
Human bladder carcinoma (S637)-conditioned media (BlCM).
Adherent human bladder carcinoma cells were grown in RPMI 1640 containing 0.75% (wt/vol) glutamine (100X, Gibco) and 2% FCS. Cells were cultured in 75-cm2 flasks, on Cytodex-3 beads (Pharmacia Fine Chemicals, Piscataway, NJ). Cells were grown to confluence (on beads), and media were conditioned for 3-4 d. After centrifugation, the CM were concentrated fivefold by ultrafiltration (Amicon YM-10 membrane, Amicon Corp., Lexington, MA), filter-sterilized, and stored at -80'C.
Optimal concentrations of these CM were determined by using reciprocal titrations as reported elsewhere (19). These CM were examined over a range of 0.1-30%. Each CM was titrated alone, and in the presence of the putative, synergistic regulator. The addition of known synergistic activities (e.g., PMA) served to unmask relatively weak CSAs. These concentration/responsiveness studies thus detected differential thresholds (either by examining broad ranges ofCM alone, or by coculture) or inhibitors (by dilution). However, such studies could not exclude the presence ofan inhibitory activity which had an identical response curve in both types oftitration experiment. While improbable, such an event might reduce or mask lineage-specific or nonspecific activities. The concentrations routinely used were B1CM 7.5%, HLuCM 10%, PHA-LCM 10% (final concentrations).
Tumor-promoting phorbol diesters. Phorbol diesters (Sigma Chemical Co.) were prepared as stock solutions of 10-1 M in dimethylsulfoxide and kept in the dark at -20'C until used. Fresh stock solutions were prepared every 3 wk. Immediately before use, a working solution was made using culture medium as the diluent.
Human plasma samples. Plasma was taken from normal volunteers after obtaining informed consent. Plasma was anticoagulated with preservative-free heparin and immediately spun (1,500 g for 20 min) to produce platelet-poor plasma. This plasma was filter sterilized (0.22 Mm) and used immediately. Normal plasma, alone, did not stimulate colony development, but was screened for the optimal concentration supporting colony growth (30-40%, final concentration).
Liquid suspension cultures. Bone marrow NALD cells were prepared as described above. After plastic adherence, the cells were subjected to nylon wool adherence to remove residual adherent cells and B lymphocytes (20) . Human marrow NALD-B cells or human erythroleukemia (HEL) cells (vide infra) were cultivated (1-2 X 105/ml) in the presence of regulatory activities for 5 or 4 d, respectively. Culture conditions were as described above.
Human recombinant hematopoietic growth factors
Recombinant human IL-3, GM-CSF, and IL-6 were the generous gift of Dr. Steven Clark, Genetics Institute, Cambridge, MA. The rh-IL-3 (lot 1039-86; sp act 0.5-1.0 X 107 U/mg) was Escherichia coli expressed and 99% pure. Human, rh-GM-CSF (lot CDI9D2-701; sp act 1 X 107 U/mg) was E. coli expressed and 99% pure. Interleukin-6 was E. coil expressed, with sp act 5 X 106 U/ml, and 2 95% pure. Recombinant IL-I was purchased from Genzyme Corporation, Boston, MA.
Solid-phase radioimmunoassay (SPRIA) for hematopoietic cell antigens
In order to define, rapidly and precisely, factor-related changes in megakaryocyte development, we developed a SPRIA to detect megakaryocyte antigens (21) . Briefly, the SPRIA used a filtration membrane as a solid support (Durapore, Millipore Corp., Bedford, MA) and antibody-bound I251-staphylococcal protein A (SPA, ICN, Irvine, CA) as a detection system. Intact, cultivated bone marrow cells (nonadherent NALD-B or HEL cells), or other target cells, were loaded into microtiter wells, and all washes and incubations were performed in situ.
Antibody binding was thus performed in a solid phase, i.e., antigens remained membrane-associated on intact cells which were affixed to the polyvinylidene membrane. Additionally, this procedure prevented cell loss due to repetitive centrifugation and wash steps.
Calculations. Specific binding was defined as the total radioactivity (cpm) bound to antibody-labeled cells minus the radioactivity due to nonspecific binding of '25l-SPA to cells and secondary antibody. Nonspecific binding was < 15% of total binding for NALD-B cells or HEL cells (5 X 10' cell per well using antibody cocktail). Controls run to determine nonspecific '251-SPA binding were (a) '25I-SPA plus cells plus secondary antibody and (b) cells plus '251I-SPA. Additional controls were run for each assay to determine the nonspecific binding of primary antibody, secondary antibody, or 1251-SPA to the polyvinylidene membrane. These controls detected alterations in membrane binding characteristics, molecular complexing of antibodies, etc. They were routinely < 1% of the nonspecific binding controls.
Antibody specificity. Three platelet/megakaryocyte-specific antibodies were used in these studies (21) . These were: anti-Factor VIIIag (Dako Corp., Santa Barbara, CA), a monospecific heterologous antibody adsorbed three times with human WBCs, RBCs, and mouse liver powder, and two monoclonal antibodies-antiplatelet glycoprotein Ilb/Illa (a generous of Dr. Robb Todd, University of Michigan), and antiplatelet glycoprotein lb (Dako Corp.).
Analysis of bone marrow cellular reactivity by immunocytochemistry (22) showed only mature and immature megakaryocyte positive for the peroxidase reaction (21) . As well, antibody specificity in the RIA system was examined by using purified human PMNs, HL60 cells, and input NALD cells. None of these controls showed specific binding differing from zero.
The final RIA concentration ofeach antibody was as follows: antiFactor VIIIag 1:1000; anti-GP Ilb/Illa 1:30; and anti-lb 1:20). In order to improve detection, a cocktail of these antibodies (each at optimal concentration) was used. All results reported were based on the signal detected using this antibody cocktail.
HEL cell culture
In order to precisely quantify factor responsiveness by RIA, human HEL cells were utilized as an additional target cell population. HEL cells are known to express many platelet/megakaryocyte-associated antigens (21, 23, 24) and previous studies from this laboratory and those below have shown that the megakaryocyte antigenic content of these cells can be regulated (21) . HEL Table I ). These colonies consisted of 3-20 small, relatively immature megakaryocytes (data not shown). Equivalent numbers of megakaryocyte colonies (of similar size) were formed using PHA-LCM as a stimulus (12.5±6, n = 4). In addition to megakaryocyte-stimulating activity (Mk-CSA), both CM contained erythroid burst-promoting activity (BPA; Table I ). Both CM also stimulated granulocyte colony formation, stimulating -100 CFU-GM/ 105 cells. The low number of megakaryocyte progenitor cells responding to B1CM precluded the determination of Mk-CSA concentration-dependent responsiveness using this CM alone. The responsiveness of megakaryocyte progenitor cells to differing concentrations of this second, synergistic activity is presented in Fig. 2 . In the presence of optimal concentrations of B1CM (7.5%, vol/vol), HLuCM significantly augmented megakaryocyte colony development over a range of 2.5-20%
(vol/vol) with optimal, plateau colony formation occurring at 2.5%. This amplification of megakaryocyte colony development was lineage specific inasmuch as no change was seen in granulocyte colony numbers at any concentration (Table I , titration data not shown).
Substitution of tumor-promoting phorbol diesters for biological activities regulating human megakaryocyte development. In a variety of cell systems, tumor-promoting phorbol diesters such as 4fl-phorbol 1 2-myristate 13-acetate (PMA) are known to induce cellular differentiation (29) (30) (31) (32) . Examination of the effects of PMA on human bone marrow (NALD) cells shows that PMA, alone, lacks the ability to promote human megakaryocyte colony formation (i.e., it is not a Mk-CSA). However, tumor-promoting phorbols do substitute for HLuCM in augmenting megakaryocyte colony formation (Table I) tions tested) were noted on granulocyte progenitor cell frequency. Thus, B1CM alone stimulated 100±37 granulocyte colonies/ 105 cells whereas B1CM plus 10-8 M PMA resulted in 107±17 colonies. The responsiveness of human megakaryocyte progenitor cell to PMA was narrowly restricted (Fig. 3 ) with significant increases in colony numbers occurring at 6 X I0-9 M and optimal effects seen at 1O-8 M (EC50 = 7 X 10-9 M).
Examination ofthe structure-activity relationship between various phorbol esters and megakaryocyte colony development indicates that the active tumor promoters PMA and phorbol 12,13-dibutyrate were capable of substituting for biological activities that augment megakaryocyte colony formation (Table II) . In contrast, the non-tumor-promoting parent alcohol (phorbol) as well as dimethylsulfoxide (the vehicle) did not enhance megakaryocyte colony development.
Role of recombinant human hematopoietic growth factors in megakaryocyte development. In order to identify hematopoietic factors capable of regulating megakaryocyte development, we examined recombinant human IL-3, IL-6, IL-I, erythropoietin, and GM-CSF for their solitary ability to support megakaryocyte colony formation, or for their capacity to augment CSF-driven colony formation. IL-3 alone supported colony formation over a range of 100-1,000 pg/ml (Fig. 4) . Nonetheless, addition of PMA to IL-3-containing cultures significantly augmented colony formation at all concentrations of IL-3 tested. GM-CSF stimulated equivalent megakaryocyte colony formation but required an approximate 100-fold increase in concentration (Table I) . Synergistic interactions also occurred between GM-CSF and phorbol diesters. Thus, at 300 ng of GM-CSF, 4±1 megakaryocyte colonies per 105 TNC were observed, whereas addition of 0O-8 M PMA yielded 48±23 colonies (mean±SD; n = 3). Finally, recombinant erythropoietin, IL-1 or IL-6 did not show solitary colony stimulating or synergistic interactions when tested (0-100 and 0.1-10.0 U/ml, respectively) against IL-3 in a range of 0.1-1,000 ng/ml (n = 4; data not shown).
Morphologic analysis ofmegakaryocytes grown in suspension phase cultures. A substantial increase in size and colony cellularity (3-100 megakaryocytes) occurred when progenitor cells were grown under optimal conditions (data not shown). Morphologic analysis of megakaryocytes grown in suspension cultures shows great differences in megakaryocyte phenotype (Table III) . When cultured for 5 d in the presence of Mk CSA, megakaryocytes had a high nucleus/cytoplasm ratio, were of small size, and contained low amounts of megakaryocytic antigens (as visualized by immunoperoxidase). The addition of PMA or HLuCM to B1CM containing cultures resulted in a reversal of the nucleus/cytoplasm ratio (i.e., an increased cytoplasmic content), a larger size, and a subjective increase in antigenic content/megakaryocyte. Interestingly, the addition of HLUCM or PMA to BlCM-containing cultures increased the number of antigen-positive cells in these cultures. HLu-CM or PMA also increased the maturity of developing megakaryocytes in a concentration-dependent manner (Table III) .
Factor-related increases in megakaryocyte antigens. The use of a SPRIA has the advantage of being an accessory cellfree system which allows a sensitive, rapid, and independent confirmation of regulatory differences in in vitro megakaryocyte development (21) .
Two major sources ofvariability exist in the bioassay phase (i.e., suspension cultures) of the SPRIA analysis. One is the presence of a detectable regulatory activity in normal plasma (vide infra). The other source of variability is the inherent biological differences in human donors. The combined plasma/marrow variability results in a large interassay variability index. However, within each assay distinct differences in factor-stimulated SPA binding are seen. A notable difference between the semisolid and suspension culture systems is the detection of a regulatory activity in the plasma of normal individuals (Fig. 5 A) . Using BSA media as a control for the amount ofprotein in these cultures, the specific binding of '25I-SPA to megakaryocytes was not significantly different from input levels (23.7 pg/ 10 TNC input vs. 29.3 for 5-d BSA-conditioned cells). In contrast, the addition of 30% human platelet-poor plasma resulted in a significant increase (P . 0.05 Student's t test, two-tailed) in the total amount of megakaryocytic antigens. Plasma was prepared, fresh, for each assay inasmuch as we (and others; see references 13 and 17) found human sera to be inhibitory in colony culture systems (not shown). RIA analysis of 10 donor plasmas indicated seven stimulatory, two inhibitory, and one neutral for this megakaryocytic activity (also not shown). While significant increases in factor-driven antigenic content occurred within 5 d, synergistic interactions were not noted until days 10-12 (Fig. 5 B) . Again synergistic increases were observed with the addition of PMA or HLuCM.
These regulatory activities also induced increased antigenic expression HEL cells (Fig. 6) . As reported elsewhere (21, 23, 24) , these cells constitutively expressed megakaryocytic antigens. Stimulation with 10-1 to 10-9 M PMA resulted in a significant (P < 0.05) increase in antigenic expression. Simi (12, 13, 17) . Gabrilove et al. (33) report the purification of a multilineage regulator from 5637 bladder carcinoma cells that stimulates both granulocytic and erythrocytic colonies. Thus, 5637 conditioned media (BICM) contains at least one regulator with multilineage effects. Alternatively, these bladder carcinoma cells may produce other factors affecting megakaryocytes, one or more of which is present in limiting (suboptimal) concentrations.
To establish which factors in these complex media might control megakaryocyte proliferation, we examined the actions of rh-IL-3 and GM-CSF. Both factors support proliferation of megakaryocyte progenitor cells, but limited maturation. These observations extend and confirm previous reports of murine megakaryocyte colony formation in the presence of recombinant growth factors (7) . While colony numbers are higher in the presence of recombinant factors than in CM, development is suboptimal unless another regulatory factor is present (e.g., PMA). Phorbol diesters increase colony number and size presumably by increasing cell/colony detection due to increased cellular maturation (vide infra). Nonetheless, the use ofrecombinant growth factors and PMA as a substitute for the biological co-regulator (see References 10 and 11 and Results) allows unambiguous confirmation of the need for two factors in megakaryocyte proliferation and differentiation.
Our data show that B1CM, hr-IL-3, or hr-GM-CSF stimulates a low number of small (immature) megakaryocytes. The addition of a synergistic co-regulator present in HLuCM (or its substitute PMA) to these cultures increases the number, size, cytoplasmic content, antigenic content, and maturity of developing megakaryocytes. The increase in the number ofdeveloping megakaryocytes suggests that this activity either augments proliferation (without supporting colony formation) or, alternatively, regulates the expression of megakaryocyte antigens making previously unrecognizable cells antigen-positive. This latter hypothesis is substantiated by the observation of increased numbers of antigen-positive megakaryocytes in sus-pension cultures. The actions ofthis auxiliary regulatory activity are lineage specific inasmuch as neither HLuCM (or its substitute PMA) support or affect granulocytic colony formation. Further, this activity is not a function of erythropoietin, IL-1, or IL-6 in that these recombinant proteins fail to support megakaryocyte colonies either alone or in conjunction with sources of IL-3.
The detection of increased megakaryocyte antigenic determinants by SPRIA independently substantiates our observations of megakaryocyte development in human bone marrow cultures. In a suspension culture system, HLuCM or PMA stimulation increases antigen levels over that seen with BICM alone. Interestingly, comparison ofplasma-containing cultures and cultures containing and an equivalent amount of BSA indicates that normal human plasma contains low, but detectable, levels of this synergistic regulator. The SPRIA detects total megakaryocyte antigenic content (per lIO TNC) which is a function of both the number and size ofthe megakaryocytes. Thus, the assay does not distinguish between proliferation or differentiation events. However, the morphologic and quantitative analysis of cultured m, egakaryocytes described above makes possible such distinctions.
It is interesting that the sensitivity ofthe SPRIA is such that differences in factor-driven increases in antigenic regulation are observed within 5 d of incubation (vs. 14-16 d for colony detection). Antigenic content continues to increase in suspension until days 10-12 at which point synergistic growth factor interactions are observed. These differences in regulation are presumably due to technical (liquid vs. semisolid culture) or biological considerations which are currently under investigation.
Both PMA and the biological source of the synergistic megakaryocyte regulator (HLuCM) also stimulate megakaryocyte antigen expression in HEL cells. These observations confirm and extend the work of Papayannopoulou et al. (23) and others (24) showing the presence and induction of megakaryocyte antigens in HEL cells. Importantly, we show that a biological activity capable of influencing the development of native human megakaryocytes also effects megakaryocytic expression in HEL cells. This implies the presence of a receptor for such an activity(ies) and suggests the usefulness ofthis cell line as a model for studies on the mechanisms of megakaryocyte development.
The actual target cell(s) for the actions ofIL-3, GM-CSF, or the secondary synergistic activity are unknown. Two potential megakaryocyte target cell populations exist in suspension cultures: megakaryocyte progenitor cells, and immature megakaryo'cytes. Such immature cells are observed in immunocytochemically labeled NALD cell populations (34, and M. Long, unpublished observations). These studies utilize partially fractionated (NALD) cells at limiting dilutions (50,000/ ml), suggesting that accessory cells play a minor, ifany, role in factor responsiveness. However, the use of CM rather than purified activities, and accessory cell-depleted (NALD-B) rather than purified cells, makes direct assessment of the role of these factors and their targets difficult. Thus, it cannot be concluded that accessory cells are not involved in these studies, or that more than one synergistic regulator is present. Given these limitations, further characterization of the role of the co-regulator and its target cells must await purification of the synergistic regulatory factor and the use of purified target cell populations.
Two-tiered regulation of human megakaryocyte development was first described by Harker 
